Biogen Soars 46% on Alzheimer’s Drug Trial. Mizuho Raises the Stock to Buy.

Biogen Soars 46% on Alzheimer’s Drug Trial. Mizuho Says the Stock Is a Buy. | Barron’s


Biogen

shares were soaring Wednesday after the biopharmaceutical company said that its experimental Alzheimer’s drug with Japan-based partner 


Eisai

showed promising results.

Guggenheim Securities analyst Yatin Suneja called the data “a new dawn for Alzheimer’s treatment.”

Leave A Reply

Your email address will not be published.